Bushen Culuan Decoction
Hyperprolactinemia
Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hyperprolactinemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bushen Culuan Decoction (this asset) | Xiyuan Hospital of China Academy of Chinese Medical Sciences | P2 | CCC · 53 |
| Risperidone | Si Tianmei | P4 | BB |
| Paliperidone | Si Tianmei | P4 | BB |
| Bromocriptin | University Hospital, Bonn | P3 | B |
| Kisspeptin 112-121 | Massachusetts General Hospital | P1 | CC |
| Gnrh | Massachusetts General Hospital | P1 | CC |
| Metformin | Taipei Medical University Hospital | N/A | D |
Other indications for Bushen Culuan Decoction
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | P2 | CCC · 53 |
| Primary Ovarian Failure | — | P2 | CCC · 53 |
| Anovulation | — | P2 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bushen Culuan Decoction in Hyperprolactinemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bushen-culuan-decoction-hyperprolactinemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →